Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor References Abbreviations Other Indication Phase NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Phase 3 Indication NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase Phase 3 Patients 489 Patients 268 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Measures Primary Outcome Measures Target Patients Arms Intervention Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Arms Intervention Target Patients Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Arm 2: Placebo comparator Patients with active Sjogren's syndrome Read-out Primary 2026 Milestone(s) Publication TBD Read-out Milestone(s) Primary 2026 Publication TBD 54 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation